{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:06:04Z","timestamp":1791191164704,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"International Treatment Preparedness Coalition"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2022, 464 000 people died from human papillomavirus (HPV)\u2013related cancer. Despite the availability of safe, highly effective HPV vaccinations, global coverage is just 20% for girls and 7% for boys. We summarized the evidence for target vaccination age and found that vaccinating at age 9\u201310 years, the youngest end of the World Health Organization's (WHO) recommended age range, has multiple advantages. Earlier vaccination increases the likelihood of vaccinating before HPV exposure, may reduce the impact of sex-associated stigma, and is logistically advantageous through enabling primary-school immunization and program resilience. Furthermore, we systematically reviewed published immunogenicity data on children aged 9\u201315 years and identified that vaccination at age 9 is immunologically robust. Globally, most countries target ages 11 years or older for HPV vaccination. Our findings indicate an urgent need to target earlier ages to help achieve the WHO\u2019s goal to vaccinate 90% of girls against HPV by age 15.<\/jats:p>","DOI":"10.1093\/cid\/ciaf679","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:39:28Z","timestamp":1765197568000},"page":"e875-e883","source":"Crossref","is-referenced-by-count":1,"title":["Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0400-0950","authenticated-orcid":false,"given":"Edie","family":"Brassington","sequence":"first","affiliation":[{"name":"School of Public Health, Imperial College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Fairhead","sequence":"additional","affiliation":[{"name":"Acute Medicine, Royal Free London NHS Foundation Trust , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-7645","authenticated-orcid":false,"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool , Liverpool ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026043013144828400_ciaf679-B1","author":"World Health Organization"},{"key":"2026043013144828400_ciaf679-B2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/v15071440","article-title":"Recent developments in human papillomavirus (HPV) vaccinology","volume":"15","author":"Williamson","year":"2023","journal-title":"Viruses"},{"key":"2026043013144828400_ciaf679-B3","author":"Wongkalasin"},{"key":"2026043013144828400_ciaf679-B4","author":"National Cancer Institute"},{"key":"2026043013144828400_ciaf679-B5","author":"World Health Organization"},{"key":"2026043013144828400_ciaf679-B6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"2026043013144828400_ciaf679-B7","volume-title":"Immunization data","author":"World Health Organization","year":"2025"},{"key":"2026043013144828400_ciaf679-B8","author":"US Food and Drug Administration"},{"key":"2026043013144828400_ciaf679-B9","author":"European Medicines Agency"},{"key":"2026043013144828400_ciaf679-B10","author":"Burchell"},{"key":"2026043013144828400_ciaf679-B11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jadohealth.2021.10.027","article-title":"Regional and sex differences in the prevalence and correlates of early sexual initiation among adolescents aged 12\u201315 years in 50 countries","volume":"70","author":"Kushal","year":"2022","journal-title":"J Adolesc Health"},{"key":"2026043013144828400_ciaf679-B12","doi-asserted-by":"crossref","first-page":"2239085","DOI":"10.1080\/21645515.2023.2239085","article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review","volume":"19","author":"Ellingson","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013144828400_ciaf679-B13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3201\/eid2703.202721","article-title":"Oral human papillomavirus infection in children during the first 6 years of life, Finland","volume":"27","author":"Syrj\u00e4nen","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2026043013144828400_ciaf679-B14","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1017\/S0950268819001341","article-title":"Seroprevalence of HPV serotypes 6, 11, 16 and 18 in unvaccinated children from Mexico City","volume":"147","author":"Pacheco-Dom\u00ednguez","year":"2019","journal-title":"Epidemiol Infect"},{"key":"2026043013144828400_ciaf679-B15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jmv.24992","article-title":"Presence of infection and analysis of HPV subtypes in girls younger than 9 years old attended at a referral service in Esp\u00edrito Santo, Brazil","volume":"90","author":"Sartori","year":"2018","journal-title":"J Med Virol"},{"key":"2026043013144828400_ciaf679-B16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12879-022-07215-7","article-title":"Prevalence of vaginal HPV infection among adolescent and early adult girls in Jos, North-Central Nigeria","volume":"22","author":"Cosmas","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026043013144828400_ciaf679-B17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12879-022-07028-8","article-title":"Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany","volume":"22","author":"Loenenbach","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026043013144828400_ciaf679-B18","doi-asserted-by":"crossref","first-page":"e2022060993","DOI":"10.1542\/peds.2022-060993","article-title":"Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety","volume":"152","author":"Restrepo","year":"2023","journal-title":"Pediatrics"},{"key":"2026043013144828400_ciaf679-B19","doi-asserted-by":"crossref","first-page":"e28-39","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"key":"2026043013144828400_ciaf679-B20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/s12889-023-15842-1","article-title":"Barriers and facilitators of HPV vaccination in sub-Saharan Africa: a systematic review","volume":"23","author":"Kutz","year":"2023","journal-title":"BMC Public Health"},{"key":"2026043013144828400_ciaf679-B21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4274\/jtgga.galenos.2022.2022-6-6","article-title":"Barriers to the HPV vaccination program in the eastern Mediterranean region: a narrative review","volume":"24","author":"Hakimi","year":"2023","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"2026043013144828400_ciaf679-B22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13104-017-2734-2","article-title":"Facilitators and barriers to the acceptance of human papillomavirus (HPV) vaccination among adolescent girls: a comparison between mothers and their adolescent daughters in Hong Kong","volume":"10","author":"Loke","year":"2017","journal-title":"BMC Res Notes"},{"key":"2026043013144828400_ciaf679-B23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.47108\/jidhealth.Vol1.Iss1.3","article-title":"Syrian mothers, why to accept or to refuse HPV vaccine for their teen girls","volume":"1","author":"Al Saad","year":"2018","journal-title":"J Ideas Health"},{"key":"2026043013144828400_ciaf679-B24","volume-title":"Human papillomavirus vaccine acceptability among parents of adolescent girls in Mysore, India","author":"Degarege Mengist A","year":"2019"},{"key":"2026043013144828400_ciaf679-B25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.11604\/pamj.2021.38.126.21359","article-title":"Mothers of adolescent girls and human papilloma virus (HPV) vaccination in western Kenya","volume":"38","author":"Mabeya","year":"2021","journal-title":"Pan Afr Med J"},{"key":"2026043013144828400_ciaf679-B26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1037\/sah0000230","article-title":"An implication of impurity: the impact of feminine honor on human papillomavirus (HPV) screenings and the decision to authorize daughter's HPV vaccinations","volume":"6","author":"Foster","year":"2021","journal-title":"Stigma Health"},{"key":"2026043013144828400_ciaf679-B27","doi-asserted-by":"crossref","first-page":"2214054","DOI":"10.1080\/21645515.2023.2214054","article-title":"Parents\u2019 stigmatizing beliefs about the HPV vaccine and their association with information seeking behavior and vaccination communication behaviors","volume":"19","author":"McKenzie","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013144828400_ciaf679-B28","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1080\/07448481.2021.1935970","article-title":"When culture and health collide: feminine honor endorsement and attitudes toward catch-up HPV vaccinations in college women","volume":"71","author":"Foster","year":"2023","journal-title":"J Am Coll Health"},{"key":"2026043013144828400_ciaf679-B29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12889-023-17540-4","article-title":"Information needs of ethnically diverse, vaccine-hesitant parents during decision-making about the HPV vaccine for their adolescent child: a qualitative study","volume":"24","author":"Fisher","year":"2024","journal-title":"BMC Public Health"},{"key":"2026043013144828400_ciaf679-B30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2019.10.025","article-title":"Provider experience recommending HPV vaccination before age 11 years","volume":"217","author":"Biancarelli","year":"2020","journal-title":"J Pediatr"},{"key":"2026043013144828400_ciaf679-B31","doi-asserted-by":"crossref","first-page":"2251815","DOI":"10.1080\/21645515.2023.2251815","article-title":"Multilevel perspectives on school-based opportunities to improve HPV vaccination among medically underserved adolescents: beyond school entry mandates","volume":"19","author":"Shin","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013144828400_ciaf679-B32","author":"Roser"},{"key":"2026043013144828400_ciaf679-B33"},{"key":"2026043013144828400_ciaf679-B34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ypmed.2016.02.039","article-title":"Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion","volume":"89","author":"Sauver","year":"2016","journal-title":"Prev Med"},{"key":"2026043013144828400_ciaf679-B35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"2026043013144828400_ciaf679-B36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jadohealth.2011.10.009","article-title":"Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16\/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls","volume":"50","author":"Pedersen","year":"2012","journal-title":"J Adolesc Health"},{"key":"2026043013144828400_ciaf679-B37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil\u00ae in 9\u201315-year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2026043013144828400_ciaf679-B38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11427-019-9547-7","article-title":"Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women","volume":"63","author":"Hu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"2026043013144828400_ciaf679-B39","doi-asserted-by":"crossref","first-page":"2061248","DOI":"10.1080\/21645515.2022.2061248","article-title":"Long-term immunopersistence and safety of the Escherichia coli-produced HPV-16\/18 bivalent vaccine in Chinese adolescent girls","volume":"18","author":"Yao","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013144828400_ciaf679-B40","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.1016\/j.vaccine.2019.09.089","article-title":"The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9\u201313\u202fyear-old girls: is it influenced by age, menarche status or body mass index?","volume":"37","author":"Sauvageau","year":"2019","journal-title":"Vaccine"},{"key":"2026043013144828400_ciaf679-B41","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1016\/j.vaccine.2020.08.005","article-title":"A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska native children, Alaska, United States","volume":"38","author":"Bruce","year":"2020","journal-title":"Vaccine"},{"key":"2026043013144828400_ciaf679-B42","doi-asserted-by":"crossref","first-page":"e20194035","DOI":"10.1542\/peds.2019-4035","article-title":"Three-year follow-up of 2-dose versus 3-dose HPV vaccine","volume":"147","author":"Bornstein","year":"2021","journal-title":"Pediatrics"},{"key":"2026043013144828400_ciaf679-B43","doi-asserted-by":"crossref","first-page":"e214302","DOI":"10.1001\/jamanetworkopen.2021.4302","article-title":"Association of age with SARS-CoV-2 antibody response","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026043013144828400_ciaf679-B44","volume-title":"Technical synthesis of current, published evidence on single-dose HPV vaccination","author":"PATH","year":"2020","edition":"3rd ed"},{"key":"2026043013144828400_ciaf679-B45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026043013144828400_ciaf679-B46","author":"UNICEF"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf679\/65822201\/ciaf679.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e875\/65822201\/ciaf679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e875\/65822201\/ciaf679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:14:55Z","timestamp":1777569295000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/e875\/8375424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,9]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf679","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,12,9]]}}}